Lancet report names Zoloft and Lexapro as best new-generation antidepressants
This article was originally published in Scrip
Pfizer's SSRI Zoloft (sertraline and generics) and Forest Laboratories' SSRI Lexapro (escitalopram) have been named the best second-generation antidepressants in terms of safety and efficacy in a report published online in The Lancet (January 29th).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.